H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays)

Date: May 1, 2009
Pages: 60
Price:
US$ 800.00
Publisher: Kalorama Information
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H043984769FEN
Leaflet:

Download PDF Leaflet

H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays)
The outbreak of swine flu is highlighting the public health importance of improved testing techniques and providing market opportunities for manufacturers of diagnostic tests and other products related to the disease. These conclusions and others appear in a new report released from Kalorama Information: Swine Flu Market Alert by Kalorama's lead analyst, Shara Rosen.

Regardless of the eventual severity of the epidemic, there will be distinct market impact on both immunoassay and molecular test makers, according to the report. The makers of certain tests will benefit both in terms of sales and more broadly in recognition that their products play a vital role in making the public health community significantly better prepared for this possible pandemic than 1968 or before.

The report examines:
  • Market Impact likely for immunoassays and molecular testing.
  • Lessons from previous epidemics, likely impact on both immunoassays and molecular testing.
  • Overview of the H1N1 strain as compared to other.
  • Immunoassay and Molecular Test Products Available on the Market
  • Developments in the last few days of significance to the diagnostic industry.
  • Profiles of nearly 25 specific manufacturers active in this space.
The report focuses almost exclusively on the in vitro diagnostic industry as it applies to work being done by commercial entities and products that are either in development or have been brought to market.

The market assessment provided has been assembled based on publicly available information. Company sales data and other quantitative evaluations of the markets for flu diagnostics have been developed based on publicly available information and are expressed in US dollars, no adjustments have been made for currency exchange fluctuations.

Under normal circumstances, a report of this genre would be assembled from information derived from primary and secondary sources. However, in the short time it took to research and write this report, almost all of the major scientific and industry experts were occupied with the extraordinary task of preparing for a pandemic.

Therefore the information contained in this report has been assembled from a vast array of scientific and market publications, government sources, analyzed by a professional analyst.
CHAPTER ONE: EXECUTIVE SUMMARY
  • Background
  • Exhibit 1: Flu Epidemics Compared to Present 1918-Today
  • Scope And Methodology
  • Point of View
  • Information Sources

CHAPTER TWO: 2009 SWINE INFLUENZA AND OTHER FLU EPIDEMICS
  • Influenza Overview
  • Overview of Virus Types
  • What’s So Special About This Latest Flu?
  • Flu Therapeutics
  • WHO Global Influenza Preparedness Plan

CHAPTER THREE: FLU DIAGNOSTICS
  • Background
  • Exhbit 2: Influenza Test Innovations, 2009 (Company, Technology, Test Details, Status)
  • Immunoassays
    • Rapid Testing
    • Market Performance of Rapid Test
    • New Entrant Possiblity
    • Conclusion: Impact of Swine Flu on Rapid Testing
  • Molecular Assays
    • Molecular Influenza Detection Techniques
    • PCR, Sequencing or Both
    • Lessons and Market Impact of the H5N1 Epidemic

CHAPTER FOUR: PROGNOSIS FOR A/H1N1
  • Background
  • Pandemic - Where? When?
    • 1976 Hsw1N1 Swine Flu Case
    • Comparing Past Flu Epidemics to 2009
    • International Reaction
  • Swine Flu and the IVD Industry
    • Origin of Flu Virus Mixes
    • PCR Test Development
    • Late-Breaking Research Developments
    • Use of Rapid Tests in Current Epidemic

CHAPTER FIVE: COMPANIES AND PRODCUTS IMPACTED BY SWINE FLU EPIDEMIC
  • Immunoassays
    • 3M Medical Diagnostics
    • Becton, Dickinson and Company (BD)
    • Genzyme Corporation
    • Inverness Medical Innovations
    • Meridian Bioscience, Inc.
    • Quidel Corporation
    • Remel, Inc.
    • Response Biomedical Corporation
  • Molecular Tests
    • Arbor Vita Corporation
    • CombiMatrix Molecular Diagnostics (CMDX)
    • Diagnostic HYBRIDS, Inc. (DHI)
    • eGene Inc.
    • Eiken Chemical Co., Ltd
    • Life Technologies/Applied Biosystems/ Invitrogen Corporation (ABI)
    • Lab21
    • Laboratory Corporation of America Holdings (LabCorp)
    • Luminex Corporation
    • Nanogen
    • Prodesse Inc.
    • Qiagen N.V.
    • Seegene Inc.
    • Veredus Laboratories Pte
H1N1 (Swine Influenza) - Pipeline Review, Q4 2010 US$ 450.00 Dec, 2010 · 48 pages
H1N1 (Swine Influenza) - Pipeline Review, Q1 2011 US$ 450.00 Mar, 2011 · 60 pages
H1N1 Infection - Pipeline Review, H2 2014 US$ 1,800.00 Sep, 2014 · 160 pages

Ask Your Question

H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays)
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: